Insights into Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: The Role of Fibrinogen and Pepsinogen
Middle East Journal of Digestive Diseases · 31.10.2025 · 17 (4) · 240-246
DOI: 10.34172/mejdd.2025.438 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Middle East Journal of Digestive Diseases, online erschienen am 31.10.2025. Verfasst von Zahra Eslami und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Golestan University of Medical Sciences, Golestan, Iran. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Fibrinogen is a multifunctional protein that contributes to inflammatory processes. Elevated levels of fibrinogen have been associated with increased liver fibrosis and disease severity of non-alcoholic steatohepatitis (NASH). Fibrinogen appears to interact with other factors implicated in NASH pathophysiology, such as activation of immune cells to induce pro-inflammatory cytokines and cellular signaling pathways. Additionally, fibrinogen-mediated pathways may disrupt normal tissue repair processes. Pepsinogen, the inactive precursor of pepsin and a specific functional enzyme in the gastric mucosa, is a serological marker with subtypes closely related to different gastrointestinal diseases. Changes in pepsinogen levels in liver disease are not entirely understood and likely relate to many factors, including inflammation, altered gastrin levels, and Helicobacter pylori infection. The clinical implications of altered pepsinogen levels in liver disease are still under investigation, but they may have relevance in the diagnosis and monitoring of liver disease.
Methods
Databases searched included PubMed, Google Scholar, and Scopus from 2005 to 2024, and the following keywords were used: fibrinogen, pepsinogen, non-alcoholic steatohepatitis, NASH, non-alcoholic fatty liver disease, NAFLD, and fibrosis.
Results
As a potential biomarker for NASH, measuring fibrinogen levels could offer valuable insights into disease diagnosis and progression monitoring. On the other hand, pepsinogen is involved in gut health and liver function, contributing to liver inflammation and fibrosis through mechanisms like the gut-liver axis and signaling pathways.
Conclusion
Overall, both fibrinogen and pepsinogen appear to have a more significant negative impact on liver health and the progression of NAFLD than beneficial effects. Integrating assessments of fibrinogen and pepsinogen into clinical practice could facilitate earlier intervention strategies aimed at slowing disease progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Biochemistry, Golestan University of Medical Sciences, Golestan, Iran.
- Department of Clinical Biochemistry, Hamadan University of Medical Sciences, Hamadan, Iran.
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
- University of Queensland, Faculty of Medicine, Great Brisbane Medical School, Brisbane, Australia.
- Princess Alexandra Hospital, Department of Gastroenterology and Hepatology, Brisbane, Queensland, Australia.
ORCID-Profile: Zahra Eslami, Alireza Norouzi
Zitieren
APA
Eslami, Z., & Norouzi, A. (2025). Insights into Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: The Role of Fibrinogen and Pepsinogen. Middle East Journal of Digestive Diseases, 17(4), 240-246. https://doi.org/10.34172/mejdd.2025.438
Vancouver
Eslami Z, Norouzi A. Insights into Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: The Role of Fibrinogen and Pepsinogen. Middle East Journal of Digestive Diseases. 2025;17(4):240-246. doi:10.34172/mejdd.2025.438
BibTeX
@article{Eslami2025,
author = {Eslami, Zahra and Norouzi, Alireza},
title = {Insights into Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: The Role of Fibrinogen and Pepsinogen},
journal = {Middle East Journal of Digestive Diseases},
year = {2025},
volume = {17},
number = {4},
pages = {240--246},
doi = {10.34172/mejdd.2025.438}
}
EUVIMED